BioHarvest Sciences AI Stock Analysis
BioHarvest Sciences (BHST) AI Stock Analysis
BioHarvest Sciences
(TASE:BHST)
No summary available
BioHarvest Sciences (BHST) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 30.32M
- Dividend Yield
- ―
- Average Volume (3M)
- 255
- Price to Earnings (P/E)
- -7.4
- Beta (1Y)
- 2.06
- Revenue Growth
- 16.28%
- EPS Growth
- 25.27%
- Country
- Israel
- Employees
- ―
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- ―
BioHarvest Sciences Earnings Call Summary
The call presented a business undergoing a deliberate transition toward cash preservation, more selective VINIA customer acquisition and focused CDMO development. The company highlighted meaningful opportunities from the rare fragrance agreement, planned 2027 projects, potential licensing and future manufacturing revenue. However, the current quarter showed lower revenue and gross margin, wider operating and net losses, limited CDMO development revenue and reduced full-year 2026 revenue guidance. The strategic opportunities were constructive, but the near-term financial performance and outlook remained challenging.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BioHarvest revised full year VINIA direct-to-consumer revenue guidance to $31 million to $32 million, while the direct-to-consumer adjusted EBITDA outlook remains unchanged; external CDMO revenue is expected to be $1 million to $1.5 million for the full year with an adjusted EBITDA loss of $4 million to $5 million, and consolidated full year 2026 revenue is expected to be $32 million to $33.5 million with an adjusted EBITDA loss of $5.5 million to $7.5 million. The company expects VINIA benefits to begin becoming evident in the first quarter of 2027, Stage 2 of the fragrance program to be completed within 6 months to 9 months of its initiation, limited production to begin in the first half of 2027, and the agreement to generate $20 million to $30 million of revenue over 2027 and 2028; manufacturing revenue is expected in the second half of next year, 2027 CapEx is being capped below $5 million, and additional capacity would be created in 2028 at a moderate pace.
BioHarvest Sciences Peers Comparison
Overall Rating
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:BHST | Bioharvest Sciences, Inc. | 537.20 | -39.80 | -6.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.